author_facet Xiong, Jingbo
Epstein, Richard J.
Xiong, Jingbo
Epstein, Richard J.
author Xiong, Jingbo
Epstein, Richard J.
spellingShingle Xiong, Jingbo
Epstein, Richard J.
Molecular Cancer Therapeutics
Growth inhibition of human cancer cells by 5-aza-2′-deoxycytidine does not correlate with its effects on INK4a/ARF expression or initial promoter methylation status
Cancer Research
Oncology
author_sort xiong, jingbo
spelling Xiong, Jingbo Epstein, Richard J. 1535-7163 1538-8514 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/1535-7163.mct-08-0926 <jats:title>Abstract</jats:title> <jats:p>The cytotoxicity of 5-aza-2′-deoxycytidine (DAC) has been linked to demethylation of the INK4a/ARF tumor suppressor gene locus in various cell systems, but the causality of this association remains unproven. To test this assumption, we have examined the effects of DAC in two human cancer cell lines of differing INK4a/ARF promoter methylation status: MDA-MB-468 breast cancer cells in which INK4a/ARF is unmethylated and normally expressed, and DLD-1 colorectal cancer cells in which INK4a/ARF is methylated and repressed. In MDA-MB-468 cells, DAC induces cytotoxicity in the absence of any detectable increase of p14 or p16 expression, whereas small interfering RNA knockdown of p16/p14 expression fails to attenuate DAC cytotoxicity. In DLD-1 cells, DAC demethylates INK4a/ARF and restores both p16 and p14 expression at concentrations that fail to cause detectable growth inhibition or apoptosis; moreover, neither ARF nor INK4a transgene expression inhibits DLD-1 cell growth despite normalization of p14 and p16 expression. These data imply that neither of these cell lines depends on up-regulated expression of INK4a/ARF for DAC cytotoxicity. We propose that optimal anticancer use of this drug will await unambiguous identification of those DAC target genes primarily responsible for triggering growth inhibition, followed by clarification as to whether these upstream events are caused by hypomethylation or DNA damage.[Mol Cancer Ther 2009;8(4):779–85]</jats:p> Growth inhibition of human cancer cells by 5-aza-2′-deoxycytidine does not correlate with its effects on <i>INK4a/ARF</i> expression or initial promoter methylation status Molecular Cancer Therapeutics
doi_str_mv 10.1158/1535-7163.mct-08-0926
facet_avail Online
Free
finc_class_facet Medizin
format ElectronicArticle
fullrecord blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xNTM1LTcxNjMubWN0LTA4LTA5MjY
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xNTM1LTcxNjMubWN0LTA4LTA5MjY
institution DE-Gla1
DE-Zi4
DE-15
DE-Pl11
DE-Rs1
DE-105
DE-14
DE-Ch1
DE-L229
DE-D275
DE-Bn3
DE-Brt1
DE-Zwi2
DE-D161
imprint American Association for Cancer Research (AACR), 2009
imprint_str_mv American Association for Cancer Research (AACR), 2009
issn 1535-7163
1538-8514
issn_str_mv 1535-7163
1538-8514
language English
mega_collection American Association for Cancer Research (AACR) (CrossRef)
match_str xiong2009growthinhibitionofhumancancercellsby5aza2deoxycytidinedoesnotcorrelatewithitseffectsonink4aarfexpressionorinitialpromotermethylationstatus
publishDateSort 2009
publisher American Association for Cancer Research (AACR)
recordtype ai
record_format ai
series Molecular Cancer Therapeutics
source_id 49
title Growth inhibition of human cancer cells by 5-aza-2′-deoxycytidine does not correlate with its effects on INK4a/ARF expression or initial promoter methylation status
title_unstemmed Growth inhibition of human cancer cells by 5-aza-2′-deoxycytidine does not correlate with its effects on INK4a/ARF expression or initial promoter methylation status
title_full Growth inhibition of human cancer cells by 5-aza-2′-deoxycytidine does not correlate with its effects on INK4a/ARF expression or initial promoter methylation status
title_fullStr Growth inhibition of human cancer cells by 5-aza-2′-deoxycytidine does not correlate with its effects on INK4a/ARF expression or initial promoter methylation status
title_full_unstemmed Growth inhibition of human cancer cells by 5-aza-2′-deoxycytidine does not correlate with its effects on INK4a/ARF expression or initial promoter methylation status
title_short Growth inhibition of human cancer cells by 5-aza-2′-deoxycytidine does not correlate with its effects on INK4a/ARF expression or initial promoter methylation status
title_sort growth inhibition of human cancer cells by 5-aza-2′-deoxycytidine does not correlate with its effects on <i>ink4a/arf</i> expression or initial promoter methylation status
topic Cancer Research
Oncology
url http://dx.doi.org/10.1158/1535-7163.mct-08-0926
publishDate 2009
physical 779-785
description <jats:title>Abstract</jats:title> <jats:p>The cytotoxicity of 5-aza-2′-deoxycytidine (DAC) has been linked to demethylation of the INK4a/ARF tumor suppressor gene locus in various cell systems, but the causality of this association remains unproven. To test this assumption, we have examined the effects of DAC in two human cancer cell lines of differing INK4a/ARF promoter methylation status: MDA-MB-468 breast cancer cells in which INK4a/ARF is unmethylated and normally expressed, and DLD-1 colorectal cancer cells in which INK4a/ARF is methylated and repressed. In MDA-MB-468 cells, DAC induces cytotoxicity in the absence of any detectable increase of p14 or p16 expression, whereas small interfering RNA knockdown of p16/p14 expression fails to attenuate DAC cytotoxicity. In DLD-1 cells, DAC demethylates INK4a/ARF and restores both p16 and p14 expression at concentrations that fail to cause detectable growth inhibition or apoptosis; moreover, neither ARF nor INK4a transgene expression inhibits DLD-1 cell growth despite normalization of p14 and p16 expression. These data imply that neither of these cell lines depends on up-regulated expression of INK4a/ARF for DAC cytotoxicity. We propose that optimal anticancer use of this drug will await unambiguous identification of those DAC target genes primarily responsible for triggering growth inhibition, followed by clarification as to whether these upstream events are caused by hypomethylation or DNA damage.[Mol Cancer Ther 2009;8(4):779–85]</jats:p>
container_issue 4
container_start_page 779
container_title Molecular Cancer Therapeutics
container_volume 8
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
_version_ 1792344748527190019
geogr_code not assigned
last_indexed 2024-03-01T17:12:28.464Z
geogr_code_person not assigned
openURL url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Growth+inhibition+of+human+cancer+cells+by+5-aza-2%E2%80%B2-deoxycytidine+does+not+correlate+with+its+effects+on+INK4a%2FARF+expression+or+initial+promoter+methylation+status&rft.date=2009-04-01&genre=article&issn=1538-8514&volume=8&issue=4&spage=779&epage=785&pages=779-785&jtitle=Molecular+Cancer+Therapeutics&atitle=Growth+inhibition+of+human+cancer+cells+by+5-aza-2%E2%80%B2-deoxycytidine+does+not+correlate+with+its+effects+on+%3Ci%3EINK4a%2FARF%3C%2Fi%3E+expression+or+initial+promoter+methylation+status&aulast=Epstein&aufirst=Richard+J.&rft_id=info%3Adoi%2F10.1158%2F1535-7163.mct-08-0926&rft.language%5B0%5D=eng
SOLR
_version_ 1792344748527190019
author Xiong, Jingbo, Epstein, Richard J.
author_facet Xiong, Jingbo, Epstein, Richard J., Xiong, Jingbo, Epstein, Richard J.
author_sort xiong, jingbo
container_issue 4
container_start_page 779
container_title Molecular Cancer Therapeutics
container_volume 8
description <jats:title>Abstract</jats:title> <jats:p>The cytotoxicity of 5-aza-2′-deoxycytidine (DAC) has been linked to demethylation of the INK4a/ARF tumor suppressor gene locus in various cell systems, but the causality of this association remains unproven. To test this assumption, we have examined the effects of DAC in two human cancer cell lines of differing INK4a/ARF promoter methylation status: MDA-MB-468 breast cancer cells in which INK4a/ARF is unmethylated and normally expressed, and DLD-1 colorectal cancer cells in which INK4a/ARF is methylated and repressed. In MDA-MB-468 cells, DAC induces cytotoxicity in the absence of any detectable increase of p14 or p16 expression, whereas small interfering RNA knockdown of p16/p14 expression fails to attenuate DAC cytotoxicity. In DLD-1 cells, DAC demethylates INK4a/ARF and restores both p16 and p14 expression at concentrations that fail to cause detectable growth inhibition or apoptosis; moreover, neither ARF nor INK4a transgene expression inhibits DLD-1 cell growth despite normalization of p14 and p16 expression. These data imply that neither of these cell lines depends on up-regulated expression of INK4a/ARF for DAC cytotoxicity. We propose that optimal anticancer use of this drug will await unambiguous identification of those DAC target genes primarily responsible for triggering growth inhibition, followed by clarification as to whether these upstream events are caused by hypomethylation or DNA damage.[Mol Cancer Ther 2009;8(4):779–85]</jats:p>
doi_str_mv 10.1158/1535-7163.mct-08-0926
facet_avail Online, Free
finc_class_facet Medizin
format ElectronicArticle
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
geogr_code not assigned
geogr_code_person not assigned
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xNTM1LTcxNjMubWN0LTA4LTA5MjY
imprint American Association for Cancer Research (AACR), 2009
imprint_str_mv American Association for Cancer Research (AACR), 2009
institution DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161
issn 1535-7163, 1538-8514
issn_str_mv 1535-7163, 1538-8514
language English
last_indexed 2024-03-01T17:12:28.464Z
match_str xiong2009growthinhibitionofhumancancercellsby5aza2deoxycytidinedoesnotcorrelatewithitseffectsonink4aarfexpressionorinitialpromotermethylationstatus
mega_collection American Association for Cancer Research (AACR) (CrossRef)
physical 779-785
publishDate 2009
publishDateSort 2009
publisher American Association for Cancer Research (AACR)
record_format ai
recordtype ai
series Molecular Cancer Therapeutics
source_id 49
spelling Xiong, Jingbo Epstein, Richard J. 1535-7163 1538-8514 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/1535-7163.mct-08-0926 <jats:title>Abstract</jats:title> <jats:p>The cytotoxicity of 5-aza-2′-deoxycytidine (DAC) has been linked to demethylation of the INK4a/ARF tumor suppressor gene locus in various cell systems, but the causality of this association remains unproven. To test this assumption, we have examined the effects of DAC in two human cancer cell lines of differing INK4a/ARF promoter methylation status: MDA-MB-468 breast cancer cells in which INK4a/ARF is unmethylated and normally expressed, and DLD-1 colorectal cancer cells in which INK4a/ARF is methylated and repressed. In MDA-MB-468 cells, DAC induces cytotoxicity in the absence of any detectable increase of p14 or p16 expression, whereas small interfering RNA knockdown of p16/p14 expression fails to attenuate DAC cytotoxicity. In DLD-1 cells, DAC demethylates INK4a/ARF and restores both p16 and p14 expression at concentrations that fail to cause detectable growth inhibition or apoptosis; moreover, neither ARF nor INK4a transgene expression inhibits DLD-1 cell growth despite normalization of p14 and p16 expression. These data imply that neither of these cell lines depends on up-regulated expression of INK4a/ARF for DAC cytotoxicity. We propose that optimal anticancer use of this drug will await unambiguous identification of those DAC target genes primarily responsible for triggering growth inhibition, followed by clarification as to whether these upstream events are caused by hypomethylation or DNA damage.[Mol Cancer Ther 2009;8(4):779–85]</jats:p> Growth inhibition of human cancer cells by 5-aza-2′-deoxycytidine does not correlate with its effects on <i>INK4a/ARF</i> expression or initial promoter methylation status Molecular Cancer Therapeutics
spellingShingle Xiong, Jingbo, Epstein, Richard J., Molecular Cancer Therapeutics, Growth inhibition of human cancer cells by 5-aza-2′-deoxycytidine does not correlate with its effects on INK4a/ARF expression or initial promoter methylation status, Cancer Research, Oncology
title Growth inhibition of human cancer cells by 5-aza-2′-deoxycytidine does not correlate with its effects on INK4a/ARF expression or initial promoter methylation status
title_full Growth inhibition of human cancer cells by 5-aza-2′-deoxycytidine does not correlate with its effects on INK4a/ARF expression or initial promoter methylation status
title_fullStr Growth inhibition of human cancer cells by 5-aza-2′-deoxycytidine does not correlate with its effects on INK4a/ARF expression or initial promoter methylation status
title_full_unstemmed Growth inhibition of human cancer cells by 5-aza-2′-deoxycytidine does not correlate with its effects on INK4a/ARF expression or initial promoter methylation status
title_short Growth inhibition of human cancer cells by 5-aza-2′-deoxycytidine does not correlate with its effects on INK4a/ARF expression or initial promoter methylation status
title_sort growth inhibition of human cancer cells by 5-aza-2′-deoxycytidine does not correlate with its effects on <i>ink4a/arf</i> expression or initial promoter methylation status
title_unstemmed Growth inhibition of human cancer cells by 5-aza-2′-deoxycytidine does not correlate with its effects on INK4a/ARF expression or initial promoter methylation status
topic Cancer Research, Oncology
url http://dx.doi.org/10.1158/1535-7163.mct-08-0926